Abstract
In the present issue of the Scandinavian Journal of Pain the aper “Evaluation of the analgesic efficacy of AZD1940, a novel annabinoid agonist, onpost-operative pain after lower thirdmolar xtraction” by Jarkko Kalliomaki et al. [1] describes the effect of peripherally active CB1/CB2-receptor agonist in the most comonly used model of postoperative pain. The compound is novel, he methodology is impeccable, the paper is very well written, and he topic is hot, and yet everyone in the business knows that it is ard to get it published. And this is only because the drug was not ffective. Most researchers have at some point struggled to publish negative study.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
